Verastem Inc (USD)
VSTM
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 1.92 | 2.09 |
| 52-Wk Range | 0.83 | 3.66 |
| Last Close | 1.97 |
| Mkt Cap (m) | 146.47 |
| Dividend yield | - |
| ISIN | US92337C1045 |
| Volume | 2,004,289 |
| Exchange Venue | NAS |
Company Profile
Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
Key Information
| Price/Earning | - |
| Price/Book | 6.81 |
| Price/Sales | 10.25 |
| P/CF | - |
| Rev Growth (3 year avg) | - |
| EPS Growth (3 year avg) | - |
| Operating Margin % | - |
| Net Margin % | - |
| Return on Equity | - |
| Debt/Equity | - |
Documents
Prospectus
| en 12/10/2018 |
Annual Report
| en 31/12/2018 |
Financials
Income Statement
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Revenue (m) | 27 | - | ||||
| Operating Income (m) | -54 | -58 | -37 | -68 | -95 | - |
| Net Income (m) | -53 | -58 | -36 | -68 | -72 | - |
| Basic EPS | -2.07 | -1.61 | -0.99 | -1.76 | -1.12 | - |
| Avg. Diluted Shares Outstanding (m) | 26 | 36 | 37 | 38 | 69 | - |
Balance Sheet
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Current Assets (m) | 95 | 111 | 81 | 88 | 253 | - |
| Non Current Assets (m) | 3 | 2 | 2 | 2 | 24 | - |
| Total Assets (m) | 99 | 113 | 84 | 90 | 277 | - |
| Current Liabilities (m) | 9 | 10 | 11 | 17 | 37 | - |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | 89 | 102 | 72 | 58 | 124 | - |
Cash Flows
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Operating Cash Flows (m) | -37 | -46 | -29 | -57 | -75 | - |
| Capital Expenditure (m) | -2 | - | -24 | - |
Figures are quoted in USD unless stated otherwise
-
No change
$
1.97
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.